Sumitomo Dainippon Pharma Oncology Provides Update on Phase 3 WIZARD 201G Study of Ombipepimut-S Emulsion (DSP-7888) in Patients with Recurrent or Progressive Glioblastoma
/PRNewswire/ -- Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage biopharmaceutical company focused on research and development for novel cancer...
Source: prnewswire.com